Gottvall et al.3 found that anti-D was the cause of alloimmunisation in 60% of instances (Table VII). in the D antigen-negative and D antigen-positive organizations (10.7% versus 0.12%, respectively). Anti-D antibody contributed Pralidoxime Iodide to 78.4% of total alloimmunisations in our study. Conversation Anti-D was the most common culprit responsible for alloimmunisation. Additional alloantibodies found included anti-C, anti-M, anti-S and anti-c. Large-scale population-based studies are required to assess the actual magnitude of alloimmunisation in pregnant women in India. Keywords: alloimmunisation, irregular erythrocyte antibodies, pregnancy Introduction Red cell immunisation during pregnancy is a challenge that continues to task obstetricians and blood transfusionists actually 50 years after the intro of Rhesus (Rh) D prophylaxis. Anti-D prophylaxis experienced brightened the hopes that haemolytic disease of foetus and newborn (HDFN) due to D antigen incompatibility was in the last throes of existence. However, we have reached the 21st century and the burden of alloimmunisation in pregnancy is still on our backs. Pralidoxime Iodide Apart from the D antigen, other blood group antigens of the Rh system (C, c, E, e, Cw) and additional blood group systems have come into limelight. Alloimmunisation in pregnant women has been extensively analyzed in different areas of the world, with the rate of recurrence being found to range from 0.4% to 2.7% worldwide1C12. Common screening of all antenatal ladies, including D antigen-positive pregnant ones, is definitely highly debated and controversial4C6,13. Most developed countries have recommendations for screening all pregnant women for irregular erythrocyte antibodies. According to the recommendations of the English Committee for Requirements in Haematology, all pregnant women should be ABO and D antigen typed and screened for the presence of reddish cell antibodies early in pregnancy and at the 28th week of gestation13. Relating to recommendations in The Netherlands, it has been required since 1998 to display all pregnant women for the presence of irregular antibodies in the 1st trimester of pregnancy8. However, no such recommendations are adopted in developing countries like India. Moreover, published data Pralidoxime Iodide display wide variance in alloimmunisation rates between different geographic areas. Lee et al.5 suggested that program antenatal antibody screening for Chinese women may not be worthwhile except in D antigen-negative subjects or those with a prior history of haemolytic disease of the newborn. Their look at is supported by Wu et al.6. You will find limited data available on immunisation rates in pregnant women from India or within the antigens responsible for any immunisation. It is universally regarded as that there should be evidence-based recommendations for testing of alloantibodies in pregnant women in developing countries such as India for appropriate management of child birth. Materials and methods This study was planned to assess the prevalence of irregular erythrocyte antibodies and major culprits responsible for alloimmunisation in all multigravida women going to the antenatal clinics of Woman Hardinge Medical College (LHMC) and connected Smt Sucheta Kriplani Hospital Pralidoxime Iodide and Kalawati Saran Children Hospital. Smt Sucheta Kriplani Hospital is definitely a tertiary care hospital and is referred patients from in GHRP-6 Acetate and around Delhi for follow up and management during pregnancy (antenatal care) and child birth. This prospective study was carried out in the Regional Blood Transfusion Centre of our hospital over a period of 1 1.5 years, from June 2008 to December 2009. The study included 3,577 subjects and written consent was from all the ladies. The study was carried out on all the multiparous pregnant women irrespective of their period of gestation and obstetric history. Primigravidas and ladies who experienced received anti-D prophylaxis in the current pregnancy were not included in the study. For each patient, name, age, sex, obstetric history,.